Kathryn Polovitz, MD
Internal Medicine · Parker, CONPI 1457557191
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $337,186 of the $402,741 with a category attached, or 83.7%. Livanova USA, Inc. accounts for 94.1% of it on its own, with 59 other manufacturers making up the rest. Reporting peaked in 2022 at $76,083 and has fallen 55.6% since, to $33,814 in 2025. Among internal medicine clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,201 payments — averaging $335.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Livanova USA, Inc.$379K
- Greenwich Biosciences, Inc.$12K
- AbbVie$1K
- UCB, Inc.$1K
- Neurocrine Biosciences, Inc.$599
- SK Life Science, Inc.$476
- plus $8K from 54 others
What the payments were for
- Consulting fees$5000%
- Speaking & faculty fees$337,18684%
- Travel & lodging$38,32110%
- Food & beverage$26,7347%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$199,615
- VNS Therapy$125,991
- VNS - Sentiva$46,536
- Epidiolex$11,328
- VYEPTI$125
- RNS System$124
- NURTEC ODT$116
- ONGENTYS$106
- INGREZZA$106
How this compares
$402,741 in reported general payments places this provider in the 95th percentile of 1,430 internal medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Emgality PenGalcanezumab-Gnlm | 17 | $14,326 |
| Gabapentin | 17 | $2,839 |
| Divalproex Sodium ErDivalproex Sodium | 21 | $1,951 |
| Lamotrigine | 33 | $1,235 |
| Levetiracetam | 29 | $1,000 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Parker
- Beatriz LinnParker$9K
- Gilad GordonBoulder$476K
- Monica GrafalsAvon$401K
- Luke WebbColorado Springs$287K
- Samuel PiedadColorado Springs$154K
- Sophia AmbrusoLittleton$62K
- Kristine KuhnAurora$61K
- Kenneth OleszekDenver$60K
- Munni SelagamsettyColorado Springs$55K
- Robert KeithDenver$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.